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Objective: to study the changes in health-related quality of life from beginning of anticoagulation 
therapy to six-month follow-up, and to study associations of sociodemographic and clinical 
characteristics with measures of quality of life and general health status at six-month follow-
up, in individuals using oral anticoagulation due to various medical indications for the therapy.  
Method: prospective study performed at a city in the state of Paraná, Brazil, composed of 
78 patients.  Measures included the Duke Anticoagulation Satisfaction Scale and the Medical 
Outcomes Survey Short Form SF-36. Results:  mean age was 57 years (S.D.= 16) and 54% were 
women.  Compared to the beginning of therapy, there was a statistically significant improvement 
in health-related quality of life at six-month follow-up. Linear regression analyses explained 32% 
and 30%, respectively, of the variance of the Duke Anticoagulation Satisfaction Scale and of the 
general health status. There was improvement in all components of the SF-36, except Mental 
Health.  Conclusion:  The use of oral anticoagulation therapy was associated with improvement 
in health-related quality of life in the first six months of therapy. This study is longitudinal and 
therefore, has fewer limitations than cross-sectional studies published to date in the Nursing 
literature in Brazil.
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Anticoagulação oral: impacto da terapia na qualidade de vida relacionada 
à saúde ao longo de seis meses
Objetivo: estudar as mudanças na qualidade de vida relacionada à saúde do início da 
anticoagulação oral ao final de seis meses dessa terapia, e estudar as associações das 
características sociodemográficas e clínicas com as medidas de qualidade de vida e estado de 
saúde geral seis meses após o início do tratamento, em indivíduos com diversas indicações 
clínicas para anticoagulação oral. Método: estudo prospectivo realizado em um município do 
Paraná, Brasil, avaliando 78 pacientes. Foram utilizados os instrumentos Duke Anticoagulation 
Satisfaction Scale e Medical Outcomes Survey Short Form SF-36. Resultados: a idade média 
foi 57 anos (D.P.= 16) e 54% eram mulheres. Comparado com o início da terapia, houve 
melhora estatisticamente significante na qualidade de vida relacionada à saúde aos seis meses 
de seguimento. Os modelos de regressão linear explicaram 32% e 30%, respectivamente, 
da variância do Duke Anticoagulation Satisfaction Scale e do estado geral de saúde. Houve 
melhora em todos os componentes do SF-36, exceto Saúde Mental. Conclusão: O uso do 
anticoagulante oral foi associado à melhora da qualidade de vida relacionada à saúde nos seis 
meses de acompanhamento. Por ser longitudinal, esse estudo tem menos limitações que os 
estudos transversais publicados na área da Enfermagem brasileira até o momento.
Descritores: Anticoagulantes; Qualidade de Vida; Evolução Clínica; Enfermagem.
Anticoagulación oral: impacto de la terapia en la calidad de vida relacionada 
a la salud a lo largo de seis meses
Objetivo: Estudiar los cambios en la calidad de vida relacionada con la salud desde el inicio 
de la anticoagulación oral y al final de seis meses de tratamiento, y estudiar las asociaciones 
de las características sociodemográficas y clínicas con las medidas de calidad de vida y salud 
general seis meses después de iniciar la terapia, en pacientes con diversas indicaciones clínicas 
de anticoagulación oral. Método: Se realizó un estudio prospectivo en una ciudad de Paraná, 
Brasil, evaluando 78 pacientes. Las herramientas aplicadas fueron la Duke Anticoagulation 
Satisfaction Scale y el Medical Outcomes Survey Short Form SF-36. Resultados: La edad 
promedia fue de 57 años (D.E.=16) y el 54% era mujer. En comparación con el inicio de la 
terapia, se observó una mejoría estadísticamente significativa en la calidad de vida relacionada 
con la salud tras seis meses de seguimiento. El análisis de regresión representó el 32% y 
30%, respectivamente, de la varianza de la Duke Anticoagulation Satisfaction Scale y la salud 
general. Hubo una mejora en todos los componentes del SF-36, excepto la Salud Mental. 
Conclusión: El uso de anticoagulantes orales se asocia con una mejoría en la calidad de vida 
relacionada con la salud tras seis meses de seguimiento. Debido a su diseño longitudinal, este 
estudio trae menos limitaciones que los estudios transversales publicados en la Enfermería 
brasileña hasta ahora.
Descriptores: Anticoagulantes; Calidad de Vida; Evolución Clínica; Enfermería.
Introduction
Oral anticoagulation therapy (OAT) is widely used to 
prevent and manage thromboembolic events; however, 
often its usage is difficult due to the fluctuations of blood 
coagulation values which require a rigorous laboratorial 
follow-up, and consequently, causing an impact in 
the quality of life of the OAT users(1).  Studies have 
investigated various aspects of health-related quality of 
life (HRQoL) in OAT users, such as limitations due to 
medication use, hassle and burden, and psychological 
impact, both negative and positive(2).  A study was 
conducted in an academic hospital of the state of São 
Paulo to assess the association between HRQoL and 
various factors, which included duration of medicament 
use and presence of complications resulting from the 
therapy.  In this longitudinal study, 178 participants 
were interviewed and HRQoL was assessed through the 
eight domains of the Medical Outcomes Survey Short 
Form (SF-36).  The results indicated that women, older 
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adults, with diagnosis of atrial fibrillation, and with less 
than one year of OAT presented a lower HRQoL(3).  
In this study, we used the theoretical definition of 
HRQoL that focus on how much the disease or chronic 
condition, in addition to its symptoms, interfere in the 
person’s daily life, that is, how much the affected person 
perceives the manifestations of the disease and its 
treatment(4).  In the clinical setting, the evaluation of 
the psychological impact, burden and limitations, and 
satisfaction with OAT might help to support interventions 
with the objective of increasing the adherence to OAT, 
and therefore, increasing the likelihood that the person 
is within the therapeutic levels and reducing the 
incidence of adverse events such as thromboembolism 
or hemorrhages(1).
The participation of nursing professionals in clinics 
specialized in OAT is a practice still new in Brazil, although 
it has been often cited as practice in international studies. 
In the Nursing area in Brazil, recent research involving 
OAT patients have used cross-sectional designs(3,5-6), 
limiting the conclusions regarding the studied factors. 
To address some of those limitations, the current study 
was designed to follow a sample of patients during the 
first six months of OAT.  
The objectives of this work were: 1) to study the 
changes in HRQoL (evaluated by the eight components 
of the SF-36, the Duke Anticoagulation Satisfaction Scale 
[DASS], and perceived general health status) from the 
beginning of the treatment with oral anticoagulants to 
the end of six months of therapy, in a group of individuals 
initiating the treatment; 2) to study associations 
of sociodemographic and clinical characteristics (at 
baseline) with measures of DASS and general health 
status at six-month follow-up.
Methods
Study design, location of study, and sample selection
This study was a prospective and observational 
study conducted in public and private health service 
institutions of a city of the Western region of Paraná 
state, Brazil.  The study was approved by the hospital’s 
human subjects ethic committee and the study objectives 
were explained verbally and in written to all participants. 
Individuals who agreed to participate signed an informed 
consent prior to data collection.  Inclusion criteria 
included individuals 18 years and older using OAT, who 
had initiated treatment no longer than two months prior 
to enrollment.  This period is the average time needed 
to adjust the therapeutic dose of the medication, and 
it was used in a prospective cohort study of treatment 
adherence in the United States of America patients(7). 
Exclusion criteria included: individuals who were 
incapable to communicate verbally, who had previous 
diagnostic of mental diseases, or were not available to 
participate in both evaluations (baseline and six-month 
follow-up).  The enrollment of participants occurred 
between April 2008 and June 2009.
Data collection
Data were collected through individual interviews 
and medical chart review in two moments: at baseline 
(within two months of initiation of OAT) and at six 
months of OAT.  The following data were collected: 
sociodemographic (age, sex, and number of years of 
formal education) and clinical characteristics (number of 
medications beyond OAT, weekly dose and reason for 
prescription of OAT, information about the therapeutic 
interval of OAT, and presence of complications (yes/no) 
such as hemorrhagic episodes and/or thromboembolic 
events in the first six months of therapy).  Clinical 
information was collected from medical charts, while 
other information, including HRQoL measures (described 
below), were collected through self-report.
Measures of HRQoL
The Medical Outcomes Survey 36-Item Short-Form 
(SF-36)(8) was used in its Portuguese validated version(9) 
to evaluate HRQoL in the four-week period prior to the 
interview.  The SF-36 is composed of eight domains, 
each evaluated in a scale of 0 to 100, with larger values 
indicating better HRQoL in the respective domain.
The evaluation of the current general health 
status (GHS) was obtained through the question “In 
general, how do you rate your health today?”, which 
was answered using a visual analogue scale (VAS) of 10 
cm, anchored with the value 0 (worst health possible) 
on the left and 100 (best health possible) on the right. 
Higher values indicated better evaluation of the GHS, 
according to the participant’s perception at the time of 
the interview(10).
The evaluation of HRQoL specific for oral coagulant 
users was performed using the Duke Anticoagulation 
Satisfaction Scale (DASS)(2) in its version validated for 
Brazil(11), and applied to the participants at six months 
after beginning OAT.  The DASS measures the satisfaction 
with treatment and the OAT-related quality of life.  The 
scale is composed of 25 items, each with a five-point 
ordinal scale, and the sum of the items defines the total 
DASS.  Lower DASS scores indicate greater satisfaction 
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with OAT use, fewer limitations, less burden, and less 
psychological impact of the medication.
Statistical Analysis
Descriptive analysis was performed for all variables. 
For objective 1, we compared the domains of SF-36, 
DASS, and GHS at baseline and six-month follow-up 
using the paired t-test.  For objective 2, we performed 
linear regression analyses, using DASS and GHS at six-
month follow-up as the response variables.  Both models 
had the following explanatory variables: age (in years), 
sex, reason for prescription of OAT (mechanical valve 
prosthesis, atrial fibrillation, or deep vein thrombosis/
thromboembolism/other), number of comorbidities, 
and presence of complications related to the therapy 
during the first six month of treatment.  Significance 
level was set to 0.05.  Due to exploratory nature of this 
research, the significance level was not adjusted for 
multiple comparisons.  The results of this study should 
be interpreted as basis for future confirmatory studies. 
Data analysis was conducted using IBM SPSS (version 
19.0 for Mac and 20.0 for Windows).
Results
Seventy-eight individuals participate in the study, 
with a mean age of 57 years (S.D.=16), 15% with less 
than 40 years, 41% between 40 and 59 years, and 
44% with 60 years or more. In the sample, 54% were 
females, 72% were married, 6% lived alone, and 65% 
had less than eight years of formal education.  Average 
monthly family income was R$1350, but despite the low 
income, 97% of the participants paid the OAT treatment 
with their own resources.  In the baseline interview, the 
mean time of OAT use was 23 days (S.D. = 9, range: 5 
to 46), while in the second interview the average was 
184 days (S.D. = 8).  Reasons for indication of OAT 
included atrial fibrillation (35%), deep vein thrombosis 
or pulmonary thromboembolism or other (38%), and 
use of mechanical valve prosthesis (27%).  Presence 
of comorbidities were common among the participants, 
with only 17% of them presenting no other morbidity 
than the one that indicated OAT.  During the follow-
up period, 19% of the participants had at least one 
complication related to OAT, all of which were of 
hemorrhagic type.  
Results from HRQoL measures are presented in 
Table 1.  There was improvement in all domains of the 
SF-36 (p<0.002 for all domains), except for Mental 
Health (p=0.42).  The largest improvement occurred 
for Physical Aspects, followed by Emotional Aspects, 
Functional Capacity, and Pain.  Smaller improvements 
were observed for Social Aspects, General Health and 
Vitality.  There was a statistically significant improvement 
in GHS measured by the visual analogue scale at six-
month follow-up when compared to baseline (change 
of 9 points, p<0.001).  The mean DASS at six-month 
follow-up was 45 (S.D. = 14, 95% confidence interval 
= [42, 48]), which represents a low impact of the OAT 
use perceived by the participants.  Note that DASS is 
a measure of satisfaction and quality of life related to 
the use of OAT in individuals for whom the treatment is 
well-established, and therefore it was not applicable to 
the baseline interview.
Measures of HRQoL
Beginning of OAT treatment* 6-month follow-up
p-value†
Mean (S.D.) Median (Min.; Max.) Mean (S.D.)
Median 
(Min.; Max.)
SF-36 Domains
Physical Aspects 32 (44) 0 (0; 100) 73 (43) 100 (0; 100) <0.001
Emotional Aspects 61 (48) 100 (0; 100) 90 (31) 100 (0; 100) <0.001
Functional Capacity 70 (24) 77 (15; 100) 85 (18) 95 (10; 100) <0.001
Pain 64 (30) 62 (0; 100) 83 (21) 92 (21; 100) <0.001
Social Aspects 83 (26) 100 (13; 100) 91 (17) 100 (38, 100) 0.01
General Health 74 (24) 87 (10; 100) 81 (20) 92 (5; 100) 0.002
Vitality 67 (23) 70 (10; 100) 72 (18) 75 (20; 100) 0.008
Mental Health 72 (20) 76 (24; 100) 73 (17) 76 (24; 100) 0.41
General Health Status (GHS) 74 (22) 73 (11, 100) 83 (18) 85 (27; 100) <0.001
DASS N.A.‡ N.A.‡ 45 (14) 41 (26; 92)
Table 1 – Measures of health-related quality of life  (HRQoL) of participants at baseline (within 2 months from 
beginning of treatment) and at six-month follow-up of treatment with OAT.  Cascavel, PR, Brazil, 2008-2009
*OAT: Oral anticoagulation therapy;  † p-value from paired t-test; ‡ NA = Not applicable
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For the second objective, we performed two linear 
regression analyses using DASS and GHS at six-month 
follow-up as the response variables, and age, sex, reason 
for prescription of OAT, number of comorbidities, and 
presence of complications related to the therapy during 
the first six months as explanatory variables.  GHS at 
baseline was also added to the linear regression for GHS 
at six months follow-up.  Table 2 shows the results of the 
linear regression for DASS.  Only number of comorbidities 
was statistically significant (p=0.005), with individuals 
without other comorbidity and with 1 to 3 comorbidities 
presenting, on average, 17 and 4 points more in the 
DASS than individuals with 4 or more comorbidities. 
Participants without comorbidities other than the reason 
for OAT were less satisfied with the treatment impact in 
their lives than participants who had other diseases or 
conditions. Reason for prescription of OAT was nearly 
statistically significant (p=0.06), with individuals in the 
atrial fibrillation and deep vein thrombosis/pulmonary 
thromboembolism presenting higher values of DASS than 
the group with mechanical valve prosthesis.  The linear 
regression model explained 32% of the variance of DASS.
Table 2 - Linear regression for DASS six month after beginning of oral anticoagulation therapy (OAT). Cascavel, PR, 
Brazil, 2008-2009
Explanatory Variables
Coefficient
p-value
Estimative Standard Error
Age (in years) -0.19 0.12 0.12
Sex (Ref.: female) -0.39 2.98 0.89
Reason for prescription of OAT (Ref.: mechanical valve prosthesis) 0.06
Atrial Fibrillation 6.99 4.23 0.10
DVT*, PTE† and others 9.24 3.84 0.02
Comorbidities (Ref.: 4 or more) 0.005
None 17.13 5.11 0.001
1 to 3 comorbidities 4.25 3.30 0.20
Complications (Ref: 1 or more) -4.68 3.71 0.21
R2 = 0.323; adjusted R2 = 0.256
* DVT – Deep Vein Thrombosis; †PTE – Pulmonary Thromboembolism
Table 3 shows the results of the linear regression for 
GHS at six-month follow-up.  Only the GHS at baseline 
was statistically significant in the model (p<0.001), with 
R2= 0.303 (or 30% of the variance explained by the 
model).
Explanatory Variables
Coefficient
p-value
Estimative Standard Error
Age (in years) -0.04 0.15 0.79
Sex (Ref.: female) 1.38 3.81 0.72
Reason for prescription of OAT (Ref.: mechanical valve prosthesis) 0.54
Atrial Fibrillation 1.07 5.39 0.84
DVT*, PTE† and others 4.93 4.90 0.32
Comorbidities (Ref.: 4 or more) 0.58
None 4.94 6.69 0.46
1 to 3 comorbidities -1.44 4.27 0.74
Complications (Ref: 1 or more) 0.43 4.74 0.93
General Health Status (GHS) at baseline 0.43 0.09 <0.001
Table 3 – Linear regression for general health status (GHS) measured by a visual analogue scale (VAS) at six months 
after beginning of oral anticoagulation therapy (OAT). Cascavel, PR, Brazil, 2008-2009
R2 = 0.303;  adjusted R2 = 0.222
* DVT – Deep Vein Thrombosis; †PTE – Pulmonary Thromboembolism
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Discussion
Among the participants, there was a large 
proportion of women, with age of 60 years or older, and 
with atrial fibrillation.  The proportion of older adults 
using OAT has increased around 7% per year in Brazil(12), 
maybe because this age group presents comorbiditites 
that require use of OAT.  Furthermore, the incidence of 
atrial fibrillation increases with age(13), and studies have 
shown a large proportion of individuals 60 years or older 
who use OAT(7,13-15) for that reason.
Our evaluation of HRQoL showed that there was an 
improvement in perceived health status and in the impact 
of OAT in the first six months of the therapy according 
to the three instruments we used: SF-36 (statistically 
significant improvement in all domains, except for Mental 
Health); GHS (statistically significant improvement); 
and DASS (small perceived impact of OAT).  We did not 
find longitudinal studies of HRQoL in the literature that 
would allow us to compare our results in this population. 
Currently, we can only compare our results to cross-
sectional studies conducted in other countries(2, 16-18) and 
in Brazil(3).  For the SF-36, Social Aspects was the domain 
that had the highest scores at baseline and six-month 
follow-up.  Similar results were observed in a study in 
Brazil(3) and in international studies(7,14).  Other studies 
presented higher scores in other domains, such as Mental 
Health(18) and Emotional Aspects(16); however, in general, 
the participants of those studies were in different phases 
of the treatment with OAT.  In our study, the domain 
with the worst score was Physical Aspects at baseline 
and Vitality at six-month follow-up.  In contrast, other 
studies showed the following domains as the most 
compromised by OAT: Vitality(18), Pain(16), General Health 
(17), and Physical Aspects(2-3).  In our study, at six-month 
follow-up, participants presented higher scores for all SF-
36 domains than two of the reviewed studies(2-3), which 
evaluated individuals with longer duration of therapy 
(four and seven years, respectively).  The only domain 
in our study that did not show a statistically significant 
change between baseline and six-month follow-up was 
Mental Health (scores of 72 and 74, respectively).  In 
other studies, those values varied from 61 to 76(2,3,16,18).
Results from perceived general health status (GHS) 
showed improvement from baseline to six-month follow-
up (mean change of 9 points, p<0.001), indicating that 
the participants, on average, perceived their health as 
better after starting OAT.
Regarding quality of life related to OAT, the results 
from the instrument DASS showed that the perceived 
impact of OAT was small.  Since DASS is a relatively 
new instrument, publications using it are mostly of 
methodological nature, focusing on the psychometric 
properties of the instrument(2,11).  On those studies, 
the mean DASS was 54 and 58, which are higher 
values than the values in our study, indicating that our 
participants perceived a better quality of life related to 
OAT (lower scores represent higher satisfaction with 
OAT, less limitation, less hassle and burden, and less 
psychological impact).
In our study, individuals with deep vein thrombosis 
or pulmonary thromboembolism reported lower scores 
in HRQoL measures than individuals with mechanical 
valve prosthesis.  We could not find information in 
the literature that could explain that difference.  One 
possible explanation is the presence of pain among 
individuals with deep vein thrombosis or pulmonary 
thromboembolism.  However, persons with mechanical 
valve prosthesis could also experience pain due to the 
surgical incision.  It is possible that this latter group had 
time to prepare for the procedure (which is elective), and 
consequently, prepared for the OAT use.  In contrast, 
the group with deep vein thrombosis or pulmonary 
thromboembolism had an acute event, which could have 
surprised them with its risk of imminent death, followed 
by the necessity of OAT and its demands for health care.
In the multiple linear regressions, the models 
explained 32% of the variance of DASS and 30% of 
the variance of GHS.  Despite their clinical importance, 
the explanatory variables explained little of the 
variance of the response variables. We expected that 
the models would explain more of the variance, given 
that the 83% of the participants presented chronic 
conditions other than the reason for OAT and which 
also demand care, possibly making the participants to 
accept the implications that come with the treatment 
by OAT, and bringing less negative impact to their 
lives.  The same reasoning can be used for number 
of medications used.  For a person who already has 
the habit of taking daily medication for other chronic 
conditions, to add one more medication in the daily list 
might cause a lesser impact in their routine than the 
impact in the routine of a person who has to create the 
habit of taking the medication at the prescribed dose 
and times.  A possible negative impact of prescribing 
OAT to a person who already takes other medications 
is the cost for the person and the family, which could 
interfere in the adherence to the treatment.  However, 
among the participants of our study, it seems that cost 
was not the most important factor and it did not seem 
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to interfere negatively in their HRQoL.  One explanation 
is that most participants had enough income and/or 
were helped by their families to acquire the medication. 
This fact was collected empirically by one of the 
authors during the interviews.  Another study focusing 
on the perception of the OAT impact in the person’s 
life, showed that many people abandon their old daily 
routines to adapt to the demands of OAT, which can 
bring some negative impact to their HRQoL, especially 
during the first few months of the treatment(1). 
However, despite the changes in routine required by 
OAT, there are individuals who report a positive impact 
in their lives, either because they feel protected from 
thromboembolic events prevented by OAT, or because 
the addition of OAT did not change their routines as 
they already used medication that required care and 
dedication to be adherent to it.  We think that the latter 
occurred in our study, given the large number with 
other chronic conditions.
It is possible that there were influences from other 
factors in our study that could lead to some distortion 
in self-reporting, such as social desirability, which is the 
tendency that an individual has to answer question in 
a socially approved manner, in order to preserve his/
her self-image, to present him/herself in a favorable 
light, or to avoid negative consequences, such as 
reprehension(19).
We believe that our results can help to direct 
planning for health care of persons using OAT, in issues 
related to reasons for prescription of OAT, changes in 
daily routine generated by OAT, and re-organization of 
health care to attend those demands. This study was 
important because it characterized the population being 
followed in our healthcare system as well as because it 
pointed to directions that need to be further investigated 
given the heterogeneity of the population and their 
response to the OAT.  
One of the limitations of this study was the 
sample size, which was of moderate size but might not 
have been sufficient to study such a heterogeneous 
population.  The data collection was done in two times 
only, which might not have been sufficient to describe 
the individual’s trajectory during the period of adaption 
to OAT.  In addition, the time between OAT initiation 
and the first interview, varied somewhat (within two 
months). Finally, the scarcity of options of valid and 
reliable instruments to measure HRQoL related to OAT, 
allowed us too few choices and at this point, there is not 
enough evidence that the measures we used are the 
best ones for the Brazilian population.
Conclusions
OAT can generate a negative impact in the lives 
of its users, given the routine necessary to maintain 
the treatment.  This study contributed to the literature 
with the clinical evolution of OAT users, showing that it 
caused a positive impact in the individuals’ lives at the 
end of six months of OAT.  Future studies with larger 
sample sizes and longer follow-up periods are needed to 
increase our understanding of the oral anticoagulation 
therapy in the HRQoL of its users.
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